Mizuho Securities USA LLC Boosts Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

Mizuho Securities USA LLC increased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 46.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,875 shares of the medical device company’s stock after acquiring an additional 5,963 shares during the quarter. Mizuho Securities USA LLC’s holdings in Cooper Companies were worth $1,735,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Cooper Companies in the 4th quarter worth approximately $691,000. Highland Capital Management LLC purchased a new position in shares of Cooper Companies in the fourth quarter worth $4,004,000. Caprock Group LLC bought a new position in shares of Cooper Companies during the fourth quarter worth $282,000. Franklin Resources Inc. grew its stake in Cooper Companies by 194.0% during the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after acquiring an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after acquiring an additional 14,687 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

COO has been the subject of a number of research analyst reports. Citigroup reduced their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Stifel Nicolaus decreased their price objective on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Morgan Stanley cut their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. JPMorgan Chase & Co. lowered their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Finally, Robert W. Baird lowered their price target on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Stock Performance

Cooper Companies stock opened at $83.70 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm has a market capitalization of $16.74 billion, a P/E ratio of 42.92, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 1-year low of $77.05 and a 1-year high of $112.38. The company’s 50-day moving average is $89.80 and its 200 day moving average is $97.72.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The firm had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.